Heidelberg, November 02, 2006 – LION bioscience AG is also in the second quarter of the current fiscal year 2006/07 close to breakeven. The second quarter reported a minor loss in the net result of -76,000 Euro compared to -105,000 Euro in the corresponding period of previous fiscal year. This loss is a result of transaction costs in the context of the acquisition of SYGNIS Bioscience GmbH & Co. KG, whose assets and liabilities are consolidated for the first time at book value. However, the operating result of SYGNIS Bioscience GmbH & Co. KG will be consolidated by LION as of the third quarter.
